Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
S. Xu
Institution:
Third Affiliated Hospital of Harbin Medical University
Observed institutions:
Shanghai Medical College of Fudan University,
Harbin Medical University,
Fudan University,
Third Affiliated Hospital of Harbin Medical University,
Zhongshan Hospital,
First Hospital of China Medical University
show all 6
ORCID:
0009-0002-0984-9126
Observed ORCID:
0009-0002-0984-9126
OpenAlex ID:
A5084003494
Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer
2012
·
J. Ning
, J. Zhang
, et al.
·
European Journal of Histochemistry
·
48
PDF
Gene expression profiling analysis of lung adenocarcinoma
2016
·
H. Xu
, J. Ma
, et al.
·
Brazilian Journal of Medical and Biological Research
·
43
PDF
81MO Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated results
2022
·
C. Lyu
, W. Fang
, et al.
·
Annals of Oncology
·
12
P2.03-047 The Main Treatment Failure Pattern for Completely Resected Stage II–IIIA (N1–N2) EGFR-Mutation Positive Lung Cancer
2017
·
S. Xu
, W. Zhong
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
4
Citation count:
103
H-index:
3
I10-index:
3
Year
Topic
Type